Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication

Antiviral Therapy

Volumn 13, Issue 5, 2008, Pages 675-685

  Stöhr, Wolfgang ^a   Back, David ^b   Dunn, David ^a   Sabin, Caroline ^c   Winston, Alan ^d   Gilson, Richard ^c   Pillay, Deenan ^c   Hill, Teresa ^c   Ainsworth, Jonathan ^e   Pozniak, Anton ^f   Leen, Clifford ^g   Bansi, Loveleen ^c   Fisher, Martin ^h   Orkin, Chloe ⁱ   Anderson, Jane ^j   Johnson, Margaret ^k   Easterbrook, Phillippa ^l   Gibbons, Sara ^b   Khoo, Saye H ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UK   (United Kingdom)

ⁱ BARTS HEALTH NHS TRUST   (United Kingdom)

^j HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^k ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MONITORING; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TUBERCULOSIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; VIRAL LOAD;

EID: 49949084478     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
2. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155.
3. Zhou XJ, Sheiner LB, D'Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 1999; 43:121-128.
4. De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54:378-385.
5. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73:20-30.
6. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47:130-137.
7. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10:937-943.
8. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV nonnucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61:148-154.
9. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
10. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-1495.
11. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18:2391-2400.
12. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40:1358-1361.
13. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
14. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-566.
15. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8:86-91.
16. Saitoha A, Sarlesa E, Capparellia E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21:2191-2199.
17. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
18. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006; 62:267-275.
19. Benedek I, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers. 12th World AIDS Conference. 28 June-3 July 1998, Geneva, Switzerland. Abstract 42280.
20. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-690.
21. Ramachandran G, Agibothu Kupparam HK, Sikhamani R, et al. Influence of body weight, CYP2B6 G516T polymorphism and rifampicin co-administration on the pharmacokinetics of efavirenz in HIV-1-infected patients in South India. 4th IAS conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEB003.
22. Manosuthi W, Sungkanuperph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy or without rifampicin. Clin Infect Dis 2006; 43:253-255.
23. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450-453.
24. Pujari S, Bele V, Joshi K, et al. Effect of rifampin hepatic induction on nevirapine levels in Indian volunteers. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 574.
25. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. Aids 2005; 19:1541-1543.
26. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Aids 2005; 19:1481-1486.
27. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-1302.
28. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007; 5:349-353.
29. Pozniak AL, Miller RF, Lipman MC, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005; 6 Suppl 2:62-83.
30. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
31. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. Aids 2007; 21:733-737.
32. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet 2007; 46:109-132.
33. Carlin JB, Li N, Greenwood P, Coffey C. Tools for analyzing multiple imputed datasets. The Stata Journal 2003; 3:226-244.
34. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28:964-974.
35. StataCorp. Stata Statistical Software: Release 9. 2005. College Station, TX: StataCorp LP.
36. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. 1999. (Accessed 7 Mar 2008). Available from: http://www.fda.gov/cder/guidance/ 2635fnl.pdf.
37. Sustiva. Prescribing Information. 2007. Princeton, NJ, USA; Bristol-Myers Squibb Company.
38. Viramune. Prescribing Information, 2007. Ridgefield, CT, USA; Boehringer-Ingelheim Pharmaceuticals, Inc.
39. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
40. Robinson P, Lamson M, Gigliotti M, Myers M. Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifampin (RMP). 12th World AIDS Conference. 28 June-3 July 1998, Geneva, Switzerland. Abstract 60623.
41. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006; 42:36-41.
42. DeJesus E, Piliero PJ, Summers K, et al. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2006; 50:3157-3159.
43. Prezista. Prescribing Information. 2007. Raritan, NJ, USA; Tibotec Therapeutics, Division of Ortho Biotech Products, L.P.
44. Kaletra. Prescribing Information. 2007. North Chicago, IL, USA, Abbott Laboratories.
45. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005; 56:380-387.
46. Dailly E, Tribut O, Tattevin P, et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 2006; 62:523-526.
47. Droste JA, Kearney BP, Hekster YA, Burger DM. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:37-43.
48. Breske A, Kruse G, Lehmann S, Kurowski M. Nevirapine trough concentrations in HIV-infected patients treated with or without tenofovir. 10th European AIDS Conference. 17-20 November 2005, Dublin, Ireland. Abstract 4.3/10.
49. Davis C, Gilliam B, Amoroso A, et al. Lack of Pharmacokinetic (PK) Interaction of Tenofovir (TDF) and Emtricitabine (FTC) on Nevirapine (NVP). 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract P4.1/03.
50. Rotger M, Colombo S, Furrer H, Decosterd L, Buclin T, Telenti A. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther 2007; 12:115-118.
51. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2007. (Accessed 7 Mar 2007). Available from: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf.
52. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006. (Accessed 7 Mar 2007). Available from: http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf.